دورية أكاديمية
Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer
| العنوان: | Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer |
|---|---|
| المؤلفون: | Meteran, Hanieh, Knudsen, Anja &Ør, Jørgensen, Trine Lembrecht, Nielsen, Dorte, Herrstedt, Jørn |
| المصدر: | Meteran , H , Knudsen , A Ø , Jørgensen , T L , Nielsen , D & Herrstedt , J 2024 , ' Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer ' , Journal of Clinical Medicine , vol. 13 , no. 3 , 897 . https://doi.org/10.3390/jcm13030897Test |
| سنة النشر: | 2024 |
| المجموعة: | University of Southern Denmark: Research Output / Syddansk Universitet |
| مصطلحات موضوعية: | histone deacetylase inhibitor, ovarian cancer, platinum-sensitive recurrence, vorinostat |
| الوصف: | Background: This phase II study evaluated the efficacy and safety of the histone deacetylase (HDAC) inhibitor, vorinostat, administered in combination with paclitaxel and carboplatin in patients with platinum sensitive recurrent ovarian cancer. Methods: Women with recurrent platinum-sensitive ovarian, peritoneal, or Fallopian tube carcinoma, a performance status of 0–2, and good overall organ function were eligible. Patients received 6 courses of paclitaxel (175 mg/m 2 ) and carboplatin area under the curve (AUC) of 5.0 mg/mL/min administered via intravenous infusion on day 1 of a 3-week schedule. In addition, patients received vorinostat 400 mg orally once daily on days −4 through 10 of Cycle 1 and days 1 through 14 of each subsequent treatment cycle. The primary endpoints were progression-free survival (PFS) and adverse events. The secondary endpoints were the objective response rate and overall survival. Results: Fifty-five patients were included. CR was obtained in 14 patients (26.4%) and PR in 19 patients (35.8%), resulting in an ORR of 62.2%. Twenty patients (37.7%) had SD. The median duration of response (DoR) was 12.6 (range 6–128) months. The median PFS was 11.6 months (95% CI, 10.3–18.0; p < 0.001). Median OS was 40.6 months (95% Cl, 25.1–56.1). The most common treatment-related adverse events (all grades) were fatigue, anemia, thrombocytopenia, neutropenia, anorexia, nausea, pain, sensory neuropathy, myalgia, stomatitis and diarrhea. Conclusions: Vorinostat combined with carboplatin plus paclitaxel was tolerable and generated significant responses including a long median overall survival in recurrent platinum-sensitive ovarian cancer. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://portal.findresearcher.sdu.dk/da/publications/84e285ba-e92e-41ab-8b4f-0b5dc758bbfaTest |
| DOI: | 10.3390/jcm13030897 |
| الإتاحة: | https://doi.org/10.3390/jcm13030897Test https://portal.findresearcher.sdu.dk/da/publications/84e285ba-e92e-41ab-8b4f-0b5dc758bbfaTest https://findresearcher.sdu.dk/ws/files/256050698/jcm-13-00897-v2.pdfTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.51C6C2F1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/jcm13030897 |
|---|